CalciMedica is trading 5.6% down at $0.58 after shareholders approved a reverse stock split ranging from 1-for-2 to 1-for-10 and expanded the company’s equity incentive plan.
- The measures increase corporate flexibility but may heighten dilution and financing concerns for investors.
- The decline is also occurring alongside a 2.47% biotech-sector pullback and weaker broader-market sentiment.